不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel:ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Palliating hematologic oncologic emergencies with radiation in the age of targeted systemic therapies: three illustrative cases.
Palliating hematologic oncologic emergencies with radiation in the age of targeted systemic therapies: three illustrative cases.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
放射肿瘤科经常处理需紧急放疗的血液肿瘤急症。随着患者生存延长、复发/难治治疗选择增多,姑息治疗应尽可能避免阻碍或延误潜在治愈性后续治疗。本文介绍三种临床情形:新诊断浆细胞疾病导致脊髓压迫、危及生命且肿瘤覆盖大部分体表的皮肤淋巴瘤,以及复发/难治性弥漫大B细胞淋巴瘤肿块压迫臂丛神经、需在CAR-T 前桥接放疗。各例均采用紧急姑息放疗,同时谨慎考虑后续治疗,并依据整体治疗计划及疾病进程调整放疗方式。新疗法迅速发展使指南更新不易,参考国际淋巴瘤放射肿瘤学组等血液肿瘤专门指南及病种专家意见,有助充分姑息并保持患者接受后续疗法的资格。
Hematologic oncologic emergencies with an urgent indication for radiation are a relatively routine occurrence for the radiation oncologist. As patients are living longer and have multiple treatment options for their relapsed or refractory diseases, it is important that palliative treatments avoid precluding patients from or delaying next-line potentially curative treatments wherever possible.
We highlight the following experiences from our clinical practice: newly diagnosed plasma cell disease causing cord compression; life threatening cutaneous lymphoma with tumors covering the majority of the body surface area; and relapsed/refractory diffuse large B-cell lymphoma (DLBCL) requiring bridging radiation to a mass impinging on the brachial plexus combined with chimeric antigen receptor (CAR)-T cell therapy.
In each case, urgent palliative radiation was utilized, but the approaches were nuanced, with careful consideration of subsequent potential therapies and how the current course of radiation should be tailored for the best interplay with the overall treatment course and trajectory of the disease.
With the rapid development of new therapies, it can be difficult to stay up to date on the most recent practice guidelines. Drawing on hematologic-specific guidelines, such as those provided by the International Lymphoma Radiation Oncology Group, and disease site experts can aid in ensuring patients are appropriately palliated and eligible for future therapies.
MEMBER ACCOUNT
登录成功会直接打开下一页。